Lipid-containing osmoprotective eye drops in contact lens wearers

Abstract

Seray Aslan Bayhan, Hasan Ali Bayhan Ophthalmology Department, Bozok University Faculty of Medicine, Yozgat, TurkeyWe would like to congratulate Kaercher et al1 on their prospective study of Optive Plus (Allergan, Inc., Irvine, CA, USA) in the treatment of patients with dry eye. In this study the authors reported that Optive Plus effectively reduced the signs and symptoms of patients with all types of dry eye and they recommended the use of this artificial tear especially in lipid-deficient dry eye. We think that some important issues need more thorough discussion.View original paper by Kaercher and colleagues.